Objective:With increasing survival rates in childhood acute lymphocytic leukemia (ALL), the long-term side effects of treatment have become important. Our aim was to investigate health-related quality of life, depression, anxiety, and self-image among ALL survivors.Materials and Methods:Fifty patients diagnosed with ALL and their siblings were enrolled. The Kovacs Children’s Depression Inventory, State-Trait Anxiety Inventory, Offer Self-Image Questionnaire, and Pediatric Quality of Life InventoryTM were used for collecting data. ANOVA tests were used to determine if there were any significant differences between groups.Results:ALL survivors had higher depression, more anxiety symptoms, lower quality of life, and more negative self-image when compared to their siblings.Conclusion:Continuous diagnostic and interventional mental health services might be necessary for possible emotional side effects of treatment during and after the treatment. Rehabilitation and follow-up programs should be implemented for children during and after treatment for ALL.

The aim of this study was the determination and prospective follow-up of quality of life, depression, and anxiety in pediatric patients with cancer under chemotherapy, as well as the evaluation of related factors.Materials and methods: Fifty newly diagnosed pediatric cancer patients and their parents were prospectively monitored before, during, and after therapy, and tests were used.Results: Significantly lower quality of life scores were recorded during treatment, in the group with CNS tumors, in the group receiving chemotherapy plus radiotherapy plus surgery, in the inpatient-only treatment group, in the group receiving treatment for longer than 6 months, and in the group of patients whose diagnosis was delayed for more than 3 months. Total quality of life scores for children and their parents were 82.

Objective: We investigated the health-related quality of life (HRQL) in survivors of pediatric acute lymphoblastic leukemia (ALL) and evaluated the perceptions of the children, their siblings, and their parents. Materials and Methods: Seventy ALL survivors, who were between 7 and 17 years of age and had completed therapy ≥2 years, were included. The control group consisted of their healthy siblings. HRQL was assessed by the age-specific KINDL R questionnaire. Results: No significant differences could be found among HRQL scores of ALL survivors with respect to variables such as sex, risk group, and having chronic illness. HRQL scores for physical well-being, emotional well-being, family, and social functioning of the patient and sibling self-reports and parent proxy reports were lower than the expected values for healthy and chronically ill children. Conclusion: These results demonstrate that both ALL survivors and their families need help via psychological counseling programs to improve their HRQL even after completion of therapy.

Bu çalışmanın amacı, kanser tanısı alan ergenlerin hastalık algılarını ve depresyon, anksiyete ile olası ilişkisini incelemek ve hasta görüşmelerine yeni içerik önerileri getirmektir. Gereç ve Yöntem: Bu çalışmaya, en fazla 1 ay önce kanser tanısı almış, yaşları 14-18 arasında değişen 40 ergen (%55'i kız) katılmıştır. Ergenlerin %40'ı lenfoma, %25'i sarkoma, %15'i santral sinir sistemi (SSS) tümörü ve %20'si diğer kanser tanılarını almışlardır. Çalışmanın verileri, hastalık algısı ölçeği, Beck depresyon ve Beck anksiyete ölçekleri ile elde edilmiştir. Cinsiyet ve kanser tipi bağımsız değişkenler olarak alınmıştır. Bulgular: Yeni tanı alan ergenlerin en sık bildirdikleri belirtilerin ağrı, yorgunluk ve güç kaybı olduğu bulunmuştur. Hastalıkları üzerinde kontrollerinin olmadığına en çok inanan grubun SSS tümörü tanısı alanlar olduğu, lenfoma ve sarkoma tanıları alan grupların depresyon puanlarının diğer gruplardan anlamlı olarak fazla olduğu bulunmuştur. Sonuç: Kanser tanısı alan ergenlerin hastalık ve tedaviyle ilgili olumsuz inançlarının olup olmadığı görüşmelerde tartışılmalı ve eğer tespit edilirse daha olumlu olan bilişsel içerikle değiştirilmelidir. Ağrı gibi sıkıntı verici belirtilerin mümkün olduğunca azaltılacağı bildirilmelidir. Son olarak, tedavi boyunca depresyon, anksiyete gibi duygu durumları kontrol edilmelidir.